Bisphosphonates for Cancer Treatment Flashcards
MOA of bisphosphonates (3)
- Target osteoclasts
- Inhibit osteoclast formation and activity
- Produces greatest bone density increases of all osteoporosis therapies
Bisphosphonates:
What do the oral drugs treat?
Prevent and treatment of osteoporosis
Bisphosphonates:
Three Oral Drugs
Alendronate
Risedronate
Ibandronate
Bisphosphonates:
What do the IV treat?
Treatment of bone pathologies
Bisphosphonates:
Four IV Drugs
Etidronate Disodium
Pamidronate
Zoledronic Acid
Tiludronate
Bisphosphonates:
The specific drug used for osteoporosis prevention
Zoledronic acid
Osteonecrosis=
Death of the bone
IV Bisphosphonates are used for what types of cancers?
Treatment of advanced breast and prostate cancers and metastatic cancers to the bones
IV Bisphosphonates: What do they help with?
Help with relieving pain and high calcium levels caused by cancer that has spread to the bone
IV Bisphosphonates:
What do these help slow/delay?
Help slow the growth of cancer that has spread to the bones and help delay or prevent fractures
IV Bisphosphonates:
What has evidence shown that these drugs exert?
Antitumor properties
Adverse skeletal events are common in patients with _____ cancer, and often lead to other complications, including death.
Prostate
Five breast cancer benefits of IV Bisphosphonate Therapy
- Anti-angiogenesis that cut off blood supply to tumors
- Slowing of tumor progression
- Stimulation of immunity
- Antimetastatic
- Increase disease-free survival
Risk for BPONJ with oral meds is ____
Low
Denosumab is a new _____ drug
Osteoporosis
Denosumab is NOT a _______. It is a ____ ____
Bisphosophonate; monoclonal antibody
Denosumab Indication
Treatment of osteoporosis in postmenopausal women at high risk for fractures
Denosumab investigational in preventing bone loss associated with
- Androgen deprivation therapy in non-metastatic prostate CA
- Aromatase inhibitor therapy in breast CA
- Treatment of bone destruction caused by RA
Denosumab MOA
Receptor blocker on osteoclasts
Blocks interaction between ligand and receptor (RANK) located on osteoclast surfaces and prevents osteoclast formation
Denosumab leads to _____ bone resportion and _____ bone mass
Decreased bone resportion and increased bone mass
Denosumab: Side Effect
ONJ
Denosumab and bisphosphonates share what common target
Osteoclast inhibition
